TuHURA Biosciences, Inc.
HURA Nasdaq
SEC CIK 1498382
Follow TuHURA Biosciences
Weekly email: filings, results
Net income
−$6.4M
+9.8% vs same quarter last year
EPS, diluted
−$0.10
+28.6% vs same quarter last year
Operating cash flow
−$5M
+54.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$31M |
| FY24 | $0 | −$23M |
| FY23 | $0 | −$15M |
| FY22 | - | −$22.7M |
| FY21 | - | −$38.3M |
| FY20 | - | −$9.1M |
| FY19 | - | - |
| FY18 | - | $11.1M |
| FY17 | - | - |
| FY16 | - | $8.9M |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | −$8.3M |
| FY12 | $0 | −$2.4M |
| FY11 | $0 | −$1.3M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$27.7M |
| FY24 | −$14.8M |
| FY23 | −$12M |
| FY22 | −$20.6M |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |